- Home
- INZY vs OPFI Comparison
INZY vs OPFI Comparison
Compare INZY & OPFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INZY
- OPFI
- Stock Information
- Founded
- INZY 2015
- OPFI 2009
- Country
- INZY United States
- OPFI United States
- Employees
- INZY N/A
- OPFI N/A
- Industry
- INZY Biotechnology: Pharmaceutical Preparations
- OPFI Finance: Consumer Services
- Sector
- INZY Health Care
- OPFI Finance
- Exchange
- INZY Nasdaq
- OPFI Nasdaq
- Market Cap
- INZY 188.2M
- OPFI 174.4M
- IPO Year
- INZY 2020
- OPFI N/A
- Fundamental
- Price
- INZY $1.36
- OPFI $11.02
- Analyst Decision
- INZY Strong Buy
- OPFI Buy
- Analyst Count
- INZY 8
- OPFI 2
- Target Price
- INZY $17.75
- OPFI $7.50
- AVG Volume (30 Days)
- INZY 784.0K
- OPFI 1.8M
- Earning Date
- INZY 03-11-2025
- OPFI 03-06-2025
- Dividend Yield
- INZY N/A
- OPFI N/A
- EPS Growth
- INZY N/A
- OPFI 775.86
- EPS
- INZY N/A
- OPFI 0.38
- Revenue
- INZY N/A
- OPFI $260,661,000.00
- Revenue This Year
- INZY N/A
- OPFI N/A
- Revenue Next Year
- INZY N/A
- OPFI $6.51
- P/E Ratio
- INZY N/A
- OPFI $29.15
- Revenue Growth
- INZY N/A
- OPFI 23.85
- 52 Week Low
- INZY $1.32
- OPFI $2.35
- 52 Week High
- INZY $7.80
- OPFI $12.08
- Technical
- Relative Strength Index (RSI)
- INZY 20.27
- OPFI 68.74
- Support Level
- INZY $1.32
- OPFI $10.66
- Resistance Level
- INZY $3.18
- OPFI $8.73
- Average True Range (ATR)
- INZY 0.27
- OPFI 0.91
- MACD
- INZY -0.15
- OPFI 0.36
- Stochastic Oscillator
- INZY 2.15
- OPFI 79.82
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.
About OPFI OppFi Inc.
OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.